Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of O-hydroxyethyl chitosan/tanshinone IIA nano preparation in treatment of ischemic cerebrovascular diseases

A technology of hydroxyethyl chitosan and nano-medicine, which can be used in cardiovascular system diseases, organic active ingredients, nervous system diseases, etc., and can solve unrelated problems

Inactive Publication Date: 2018-12-25
CAPITAL UNIVERSITY OF MEDICAL SCIENCES +1
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In this application, there is no relevant data on the effect of Tanshinone IIA nano-preparation on stroke and the passage of blood-brain barrier

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of O-hydroxyethyl chitosan/tanshinone IIA nano preparation in treatment of ischemic cerebrovascular diseases
  • Application of O-hydroxyethyl chitosan/tanshinone IIA nano preparation in treatment of ischemic cerebrovascular diseases
  • Application of O-hydroxyethyl chitosan/tanshinone IIA nano preparation in treatment of ischemic cerebrovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Example 1 Tanshinone IIA nano-preparation (TIIA-NP) on the protective effect of MCAO / R rats on acute injury

[0018]This application uses rat middle cerebral artery embolism (MCAO) for 2 hours followed by perfusion for 24 hours to create an ischemic stroke model to observe the anti-acute cerebral ischemia effect of tanshinone IIA nano-preparation. Rat transient focal cerebral ischemia model was divided into 6 treatment groups, 8 rats in each group, respectively: 1) MCAO group: solvent control group, given normal saline; 2) NBP group: positive control group, given NBP 30mg 3) TIIA group: Tanshinone IIA control group, given TIIA 10 mg / kg; 4)-6) TIIA-NP group, given TIIA-NP 1, 5, 10 mg / kg respectively. Various drugs were administered 15 minutes after the ischemia in the rat transient local cerebral ischemia model, and the drugs were administered by intraperitoneal injection. One-way analysis of variance was used to test the significant difference among the groups, and the...

Embodiment 2

[0035] Example 2 Tanshinone IIA nano-preparation (TIIA-NP) to the repairing effect of chronic phase injury in MCAO / R rats

[0036] (1) Surgical modeling method As described in Implementation 1, a rat model of ischemic stroke was prepared after 2 hours of middle cerebral artery embolism (MCAO) and then reperfused for 28 days, and the differences among the groups were tested by one-way analysis of variance , to observe the repairing effect of tanshinone IIA nano-preparation on cerebral ischemia.

[0037] (2) The experiment was divided into 5 treatment groups, 10 rats in each group, respectively: 1) sham operation group: given normal saline, 2) MCAO group: the solvent control group, given normal saline; 3) NBP group: positive control 4) TIIA group: Tanshinone IIA control group, given TIIA 10 mg / kg; 5) TIIA-NP group, given TIIA-NP 10 mg / kg. Rat transient local cerebral ischemia model was administered with various drugs 15 minutes after ischemia, and the drugs were administered by...

Embodiment 3

[0040] Example 3 The ability of Tanshinone IIA nano-preparation (TIIA-NP) to cross the blood-brain barrier.

[0041] The tanshinone IIA nano-preparation was connected with a fluorescent probe, and its distribution in nude mice was observed by using small animal in vivo imaging technology. According to literature reports [7] And Thermo Fisher Scientific reagent instructions, take 10mg of nano preparations dissolved in PBS solution of pH 6.8 (0.1M), at 0 degrees, add EDCI (0.07mg) and Texas 0.02 mg, reacted for 4 hours, stopped the reaction, dialyzed, and freeze-dried to obtain the product. The nano-preparation was injected into nude mice at 50 mg / kg tail vein, and the change of fluorescence intensity was observed after administration.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The patent discloses application of a tanshinone IIA nano preparation, shown as in .1 and using O-hydroxyethyl chitosan derivative as an entrapping agent, in drugs to prevent or treat cerebral ischemia, particularly nerve injury due to local cerebral ischemia, and belongs to the technical field of nerve protection drugs. The tanshinone IIA entrapped by a nano carrier can quickly pass through the blood brain barrier. Compared with tanshinone IIA, the tanshinone IIA nano preparation has better blocking action upon nerve injury in acute stage of ischemic brain injury; threshold concentration is far lower than the concentration of tanshinone IIA. In addition, it is discovered that tanshinone IIA can promote healing of post-stroke injury and can play well by stimulating regeneration of post-ischemia endogenous nerves; tanshinone IIA entrapped by the nano carrier is more active than tanshinone IIA with the same dosage. The nano preparation herein can treat stroke-caused injury.

Description

technical field [0001] The invention belongs to the field of neuroprotective drugs, in particular to a novel neuroprotective agent against ischemic stroke damage. Background technique [0002] Stroke, coronary heart disease, and cancer are listed as three high-risk diseases that threaten human health and life. Stroke not only has the characteristics of high morbidity, high mortality, high disability rate, high recurrence rate and many complications, but also brings a heavy social burden due to poor prognosis during the treatment process. For the treatment of acute ischemic stroke, there are few effective drugs at home and abroad, and there are even rarer drugs for repairing damage after stroke. Therefore, the research and development of stroke drugs not only has high economic value, but also reflects great social value. However, a large amount of clinical experience in traditional Chinese medicine and the results of modern biomedical research suggest that Chinese medicinal...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K47/36A61K31/58A61P9/10A61P25/00
CPCA61K31/58A61K47/36
Inventor 肇玉明刘扬孙荣鑫杜立波
Owner CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com